US2025084483A1PendingUtilityA1

Methods of Detecting Bladder Cancer

79
Assignee: CEPHEIDPriority: Mar 6, 2013Filed: May 31, 2024Published: Mar 13, 2025
Est. expiryMar 6, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Leena MccannStacey Ellen WallaceEdwin Wei-Lung LaiRussell Higuchi
C12Q 2600/158C12Q 2600/106C12Q 1/6886
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).

Claims

exact text as granted — not AI-modified
1 - 73 . (canceled) 
     
     
         74 . A composition comprising a set of bladder cancer marker primer pairs comprising:
 a primer pair for detecting corticotrophin releasing hormone (CRH); and   at least one additional primer pair for detecting a marker selected from insulin-like growth factor 2 (IGF2), uroplakin 1B (UPK1B), and annexin 10 (ANXA10); and   wherein the primer pair for detecting CRH comprises a first primer comprising at least 8 contiguous nucleotides of SEQ ID NO: 35 or SEQ ID NO: 36.   
     
     
         75 . The composition of  claim 74 , further comprising at least two additional primer pairs for detecting a marker selected from the group consisting of IGF2, UPK1B, and ANXA10. 
     
     
         76 . The composition of  claim 74 , further comprising at least three additional primer pairs for detecting a marker selected from the group consisting of IGF2, UPK1B, and ANXA10. 
     
     
         77 . The composition of  claim 74 , wherein each bladder cancer marker primer pair produces an amplicon that is 50 to 500 nucleotides long. 
     
     
         78 . The composition of  claim 74 , wherein at least one bladder cancer marker primer pair spans an intron in the genomic sequence. 
     
     
         79 . The composition of  claim 74 , wherein the primer pair for detecting CRH comprises a first primer comprising at least 8 nucleotides of SEQ ID NO: 35 and a second primer comprising at least 8 nucleotides of SEQ ID NO: 36. 
     
     
         80 . The composition of  claim 74 , wherein the primer pair for detecting IGF2 comprises a first primer comprising at least 8 nucleotides of SEQ ID NO: 17 and a second primer comprising at least 8 nucleotides of SEQ ID NO: 22. 
     
     
         81 . The composition of  claim 74 , wherein the primer pair for detecting ANXA10 comprises a first primer comprising at least 8 nucleotides of SEQ ID NO: 39 and a second primer. 
     
     
         82 . The composition of  claim 74 , wherein the primer pair for detecting UPK1B comprises a first primer comprising at least 8 nucleotides of SEQ ID NO: 51 and a second primer comprising at least 8 nucleotides of SEQ ID NO: 52. 
     
     
         83 . The composition of  claim 74 , wherein the composition further comprises a set of bladder cancer marker probes, wherein the set of bladder cancer marker probes comprises a first probe for detecting an CRH amplicon, or a first probe for detecting a IGF2 amplicon, or a first probe for detecting an CRH amplicon and a second probe for detecting a IGF2 amplicon. 
     
     
         84 . The composition of  claim 74 , wherein the set of bladder cancer marker probes comprises a third probe for detecting a third amplicon selected from a ANXA10 amplicon and a UPK1B amplicon. 
     
     
         85 . The composition of  claim 74 , wherein the set of bladder cancer marker probes comprises a fourth probe for detecting a fourth amplicon selected from a ANXA10 amplicon and a UPK1B amplicon wherein the third amplicon and the fourth amplicon are different. 
     
     
         86 . The composition of  claim 83 , wherein the probe for detecting CRH comprises at least 8 nucleotides of SEQ ID NO: 21 or SEQ ID NO: 37, wherein the probe is less than 50 nucleotides long. 
     
     
         87 . The composition of  claim 83 , wherein the probe for detecting IGF2 comprises at least 8 nucleotides of SEQ ID NO: 34,wherein the probe is less than 50 nucleotides long. 
     
     
         88 . The composition of  claim 84 , wherein the probe for detecting ANXA10 comprises at least 8 nucleotides of SEQ ID NO: 40,wherein the probe is less than 50 nucleotides long. 
     
     
         89 . The composition of  claim 74 , further comprising an endogenous control primer pair or an endogenous control probe for detecting an endogenous control amplicon. 
     
     
         90 . The composition of  claim 89 , wherein the endogenous control is ABL. 
     
     
         91 . The composition of  claim 74 , wherein the composition is a lyophilized composition. 
     
     
         92 . A kit comprising the composition of  claim 91  and instructions for use.

Join the waitlist — get patent alerts

Track US2025084483A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.